A Novel Aminotetralin-Type Serotonin (5-HT) 2C Receptor-Specific Agonist and 5-HT2A Competitive Antagonist/5-HT2B Inverse Agonist with Preclinical Efficacy for Psychoses

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2014-05-01

• Fields of study

  Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1124/jpet.113.212373PMID 24563531PMCID PMC3989798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.

  2014cited by this paper
• Is schizophrenia a dopamine supersensitivity psychotic reaction?

  2014influential reference
• A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia.

  2014cited by this paper
• Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review.

  2013cited by this paper
• Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?

  2013influential reference
• Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

  2013cited by this paper
• Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

  2013influential reference
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.

  2013influential reference
• 5-HT(2C) agonists as therapeutics for the treatment of schizophrenia.

  2012cited by this paper
• Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment

  2012cited by this paper
• Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

  2012cited by this paper
• Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine

  2012cited by this paper
• The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination, and Reinstatement: Relationship to Feeding Behavior and Impulse Control

  2012cited by this paper
• A 6-week Randomized, Double-blind, Placebo-controlled, Comparator Referenced, Multicenter Trial of Vabicaserin in Subjects With Acute Exacerbation of Schizophrenia

  2011cited by this paper
• Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.

  2011cited by this paper
• The 5-HT2C Receptor Subtype Controls Central Dopaminergic Systems: Evidence from Electrophysiological and Neurochemical Studies

  2011cited by this paper
• Frontocerebellar Connectivity: Climbing through the Inferior Olive

  2010cited by this paper
• Trial of lorcaserin for weight management.

  2010cited by this paper
• Metabolic syndrome with the atypical antipsychotics.

  2010cited by this paper
• Multicenter, placebo-controlled trial of lorcaserin for weight management.

  2010cited by this paper
• Characterizing the effects of 5-HT(2C) receptor ligands on motor activity and feeding behaviour in 5-HT(2C) receptor knockout mice.

  2009cited by this paper
• Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity

  2009cited by this paper
• Impact of RNA Editing on Functions of the Serotonin 2C Receptor in vivo

  2009cited by this paper
• Serotonin 5-HT2A Receptor Function as a Contributing Factor to Both Neuropsychiatric and Cardiovascular Diseases

  2009cited by this paper
• Impact of Serotonin 2C Receptor Null Mutation on Physiology and Behavior Associated with Nigrostriatal Dopamine Pathway Function

  2009cited by this paper
• 5-HT2A and 5-HT2C receptors exert opposing effects on locomotor activity in mice

  2009cited by this paper
• (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity.

  2009influential reference
• Serotonergic drugs and valvular heart disease

  2009cited by this paper
• New Approach to 4-Phenyl-β-aminotetralin from 4-(3-Halophenyl)tetralen-2-ol Phenylacetate.

  2009cited by this paper
• Psychedelics and schizophrenia.

  2009cited by this paper
• Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors.

  2008cited by this paper
• 5-HT2CRs Expressed by Pro-Opiomelanocortin Neurons Regulate Energy Homeostasis

  2008cited by this paper
• Antipsychotic drug action: antagonism, inverse agonism or partial agonism.

  2008cited by this paper
• Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization

  2008cited by this paper
• Lifetime prevalence of psychotic and bipolar I disorders in a general population.

  2007cited by this paper
• WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity

  2007cited by this paper
• CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

  2007cited by this paper
• Neuroprotective effect of a chuk-me-sun-dan on neurons from ischemic damage and neuronal cell toxicity.

  2006cited by this paper
• Role of atypical opiates in OCD. Experimental approach through the study of 5-HT2A/C receptor-mediated behavior

  2006cited by this paper
• Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.

  2006cited by this paper
• Regional Distribution and Relative Abundance of Serotonin2c Receptors in Human Brain: Effect of Suicide

  2006cited by this paper
• Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications.

  2005cited by this paper
• Modulation of dopamine release by striatal 5‐HT2C receptors

  2005cited by this paper
• WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Anorectic Activity

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Pharmacological Characterization of AC-90179 [2-(4-Methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide Hydrochloride]: A Selective Serotonin 2A Receptor Inverse Agonist

  2004cited by this paper
• Fitting Models to Biological Data Using Linear and Nonlinear Regression: A Practical Guide to Curve Fitting

  2004influential reference
• Treatment Refractory Schizophrenia

  2004cited by this paper
• Selective stimulation of serotonin2C receptors blocks the enhancement of striatal and accumbal dopamine release induced by nicotine administration

  2004cited by this paper
• Stimulant psychosis: systematic review

  2004cited by this paper
• 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat.

  2004cited by this paper
• Constitutive Activity of the Serotonin2C Receptor Inhibits In Vivo Dopamine Release in the Rat Striatum and Nucleus Accumbens

  2004cited by this paper
• Regional distribution and cellular localization of 5‐HT2C receptor mRNA in monkey brain: Comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA

  2001cited by this paper
• Treatment-refractory schizophrenia

  2001cited by this paper
• Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin2C/2B receptor agonists: a combined in vivo electrophysiological and microdialysis study

  2000cited by this paper
• Serotonin model of schizophrenia: emerging role of glutamate mechanisms.

  2000cited by this paper
• Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.

  1998influential reference
• Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice

  1997cited by this paper
• Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors

  1995cited by this paper
• 5-HT1c receptor is a prominent serotonin receptor subtype in the central nervous system.

  1989cited by this paper
• Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents.

  1984cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Mechanisms of constitutive and agonist-induced 5-HT2B internalization, persistent endosomal signaling and paradoxical regulation of agonist pharmacology.

  2025cites this paper
• Calcium and Neural Stem Cell Proliferation

  2024influential citation
• Effects of (−)‐MBP, a novel 5‐HT2C agonist and 5‐HT2A/2B antagonist/inverse agonist on brain activity: A phMRI study on awake mice

  2023influential citation
• Structural optimizations and bioevaluation of N-H aporphine analogues as Gq-biased and selective serotonin 5-HT2C receptor agonists.

  2022cites this paper
• The effects of galangin in prepulse inhibition test and experimental schizophrenia models.

  2021cites this paper
• A new class of 5‐HT2A/5‐HT2C receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2‐aminotetralins

  2021influential citation
• Quaternized chitin used as chiral stationary phase for HPLC and the high enantioseparation of 1,2,3,4-tetrahydro-1-naphthalenamine racemates.

  2021cites this paper
• New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties

  2020cites this paper
• Lorcaserin: a review of its preclinical and clinical pharmacology and therapeutic potential.

  2020cites this paper
• The synthetic cathinone psychostimulant α-PPP antagonizes serotonin 5-HT2A receptors: In vitro and in vivo evidence.

  2019cites this paper
• Ligand‐directed serotonin 5‐HT2C receptor desensitization and sensitization

  2019cites this paper
• 1 New therapeutic opportunities for 5-HT 2 receptor ligands

  2018cites this paper
• 5-HT 2A/2B/2C Receptors, Memory and Therapeutic Targets

  2018cites this paper
• Studies on the antifungal and serotonin receptor agonist activities of the secondary metabolites from piezotolerant deep-sea fungus Ascotricha sp.

  2018cites this paper
• The Effects of Simvastatin on Experimental Schizophrenia Models in Mice

  2018cites this paper
• Serotonin 5-HT2C Receptor Activation Suppresses Binge Intake and the Reinforcing and Motivational Properties of High-Fat Food

  2018cites this paper
• 5-HT2A Receptors in the Central Nervous System

  2018cites this paper
• Pimavanserin and Lorcaserin Attenuate Measures of Binge Eating in Male Sprague-Dawley Rats

  2018influential citation
• Discovery of N-Substituted (2-Phenylcyclopropyl)methylamines as Functionally Selective Serotonin 2C Receptor Agonists for Potential Use as Antipsychotic Medications.

  2017cites this paper
• Mutagenesis Analysis Reveals Distinct Amino Acids of the Human Serotonin 5-HT2C Receptor Underlying the Pharmacology of Distinct Ligands.

  2017cites this paper
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper
• New therapeutic opportunities for 5‐HT2 receptor ligands

  2016cites this paper
• New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders.

  2016cites this paper
• Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.

  2015cites this paper
• Serotonin‐2C receptor agonists decrease potassium‐stimulated GABA release in the nucleus accumbens

  2015cites this paper
• An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist that Corrects Motor Stereotypy in Mouse Models.

  2015cites this paper
• Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.

  2015cites this paper